Results 11 to 20 of about 746 (94)

THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY

Рациональная фармакотерапия в кардиологии, 2015
Up to date antithrombotic medications applied in patients with atrial fibrillation are discussed. Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially consideredin terms of efficacy and safety of alone.
M. Yu. Gilyarov
doaj   +1 more source

Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study

Медицинский совет, 2014
The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF).
V. A. Parfyonov, S. V. Verbitskaya
doaj   +1 more source

Эндотелиальная дисфункция при моделировании экспериментального венозного тромбоза [PDF]

, 2015
ТРОМБОЗ ВЕНОЗНЫЙМОДЕЛИ НА ЖИВОТНЫХЭНДОТЕЛИЙ /ПОВРЕЖДЭКСПЕРИМЕНТЫ НА ...
Калинин, Р. Е., Новиков, А. Н., Пшенников, А. С., Сучков, И. А.   +3 more
core   +1 more source

КАРДИОВЕРСИЯ ПРИ ИСПОЛЬЗОВАНИИ РИВАРОКСАБАНА У БОЛЬНЫХ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ: РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ X-VERT

Атеротромбоз, 2015
В последнее время большое внимание уделяется применению новых пероральных антикоагулянтов (НОАК) для профилактики тромбообразования у пациентов высокого риска.
И. С. Явелов
doaj   +1 more source

NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE

Атеротромбоз, 2015
About 10% of the adult population is diagnosed with chronic kidney disease (CKD), and its presence is associated with a high risk of developing cardiovascular diseases including ventricular fibrillation (VF).
E. P. Panchenko
doaj   +1 more source

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation

Качественная клиническая практика, 2023
Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and systemic thromboembolism (embolism in the vessels of the systemic circulation, systemic embolism) in ...
A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy   +2 more
doaj   +1 more source

SUMMARY OF CONCLUSIONS FROM A CONSENSUS PANEL OF EXPERTS ON THE IMPORTANCE OF RIVAROXABAN IN THE MANAGEMENT OF PATIENTS RECOVERING FROM ACUTE CORONARY SYNDROME

Атеротромбоз, 2015
Despite the widespread introduction of primary percutaneous coronary interventions (PCI) and the use of new powerful antiplatelet drugs for the management of patients with acute coronary syndrome (ACS) at high risk, the relapse rate of coronary events ...
M. Ya. Ruda, A. I. Syrkin, E. P. Panchenko, I. S. Yavelov, O. V. Averkov, R. M. Shahnovich, A. L. Komarov   +6 more
doaj   +1 more source

Возможности радикального лечения варикотромбофлебита на фоне варикозной болезни и трофических язв [PDF]

, 2015
КОНЕЧНОСТИ НИЖНЕЙ ЯЗВАТРОМБОФЛЕБИТ /ХИРВАРИКОЗНАЯ ЯЗВАВАРИКОЗНОЕ РАСШИРЕНИЕ ВЕН ...
Захарчук, А. П., Решетняк, О. М., Тамм, Т. И.   +2 more
core   +4 more sources

Флеботромбоз в системе нижней полой вены, ассоциированный с онкологической патологией: частота, причины и диагностика [PDF]

, 2013
ТРОМБОЗ ВЕНОЗНЫЙПОЛАЯ ВЕНА, НИЖНЯЯФАКТОРЫ РИСКАНОВООБРАЗОВАНИЯПАТОЛОГИЧЕСКИЕ ...
Калинин, С. С., Хрыщанович, В. Я., Козловская, А. Н., Балашова, Д. Г., Кенденков, О. И.   +4 more
core   +1 more source

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY

Рациональная фармакотерапия в кардиологии, 2015
Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety.
D. A. Napalkov, A. A. Sokolova
doaj   +1 more source